Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durable Effect of Imeglimin on Glycemic Control in Type 2 Diabetes (DIGNITY)
NCT05366868Phase 4Active, not recruiting
- Sponsor
- National Center for Global Health and Medicine
- Start
- May 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of imeglimin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by National Center for Global Health and Medicine. Primary endpoint: Time to detection of two consecutive HbA1c levels of 7.0% or higher. Started May 2022; status: active, not recruiting.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05366868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366868.